Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!

Related Content

Transparent glass vial with clear liquid on a shadowed surface | Image credit: © Artyom - © Artyom - stock.adobe.com

Implications of the First Liquid IV Infliximab Biosimilar

ByFeliza Mirasol

November 18th 2025

Motor neuron connecting to muscle fiber, 3D illustration | Image credit: © Julian - © Julian - stock.adobe.com

What a High-Dose Nusinersen Option Means for Future SMA Care

ByFeliza Mirasol

November 17th 2025

E&L Challenges in Biologics, Part Two

BySusan Haigney,Feliza Mirasol

November 14th 2025

E&L Challenges in Biologics, Part One

BySusan Haigney,Feliza Mirasol

November 14th 2025

FDA headquarters at White Oak Campus in Silver Spring, Maryland, USA - January 13, 2020. The United States Food and Drug Administration (FDA) is a federal agency. | Image credit: © JHVEPhoto - © JHVEPhoto - stock.adobe.com

Why Biopharma Developers Should Care About FDA’s New Personalized Therapy Approval Process

ByFeliza Mirasol

November 13th 2025

Regulatory and Standard Setting Organizations Directory

Articles in this issue

Newsletter

Related Content

Implications of the First Liquid IV Infliximab Biosimilar

What a High-Dose Nusinersen Option Means for Future SMA Care

E&L Challenges in Biologics, Part Two

E&L Challenges in Biologics, Part One

Why Biopharma Developers Should Care About FDA’s New Personalized Therapy Approval Process

Trending on BioPharm International

Implications of the First Liquid IV Infliximab Biosimilar

What a High-Dose Nusinersen Option Means for Future SMA Care

Integrated Services for the Whole Drug Development Pathway

Weighing Digitalization Efficiency Against Upskilling and Quality Concerns